CI
TEVA icon

CX Institutional’s Teva Pharmaceuticals TEVA Stock Holding History

CX Institutional’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Buy
+1,600
New +$53.3K ﹤0.01% 970
2019
Q1 		– Sell
-245
Closed -$4K – 821
2018
Q4 		$4K Buy
245
+5
+2% +$103 ﹤0.01% 412
2018
Q3 		$5K Hold
240
– – ﹤0.01% 293
2018
Q2 		$6K Buy
+240
New +$4.89K ﹤0.01% 259

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CX Institutional's TEVA Position: Q2 2026 in Review

CX Institutional opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 1,600 shares worth $54K. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings. This is a return to the name: CX Institutional previously reported a position in TEVA as recently as Q4 2018.

CX Institutional first reported a position in TEVA in Q2 2018 and has held it in 4 quarters since. 108 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • CX Institutional held 1,600 shares of Teva Pharmaceuticals worth $54K as of Q2 2026.
  • Teva Pharmaceuticals was a new CX Institutional position in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #970 holding.
  • CX Institutional first reported a position in Teva Pharmaceuticals in Q2 2018 and has held it in 4 quarters since.
  • 108 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.